西藏药业：公司已将资本运作及并购成果纳入高管团队的关键绩效考核指标

Core Viewpoint - The company emphasizes the importance of capital operations and mergers and acquisitions (M&A) as part of its strategic goals, supported by strong cash flow and performance metrics for management [1] Group 1: Capital Operations - The company has sufficient cash flow that provides direct and flexible funding for ongoing M&A investments [1] - Capital operations and M&A outcomes are included in the key performance indicators for the management team [1] Group 2: Growth Strategy - The company adopts a strategy of "internal growth + external growth" to stabilize its core business while exploring new opportunities [1] - The core product, Xinhuasuan, will continue to generate stable cash flow and profit contributions in the untapped heart failure market [1] - Accelerated growth of other proprietary products will further solidify a diversified revenue base, enhancing overall risk resistance [1] Group 3: Innovation and Product Pipeline - The company is actively pursuing external M&A and innovative project layouts to build a product pipeline that combines short-term, medium-term, and long-term offerings [1] - This approach aims to reduce reliance on a single product and inject continuous growth momentum into the company [1]